论文信息 - Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. - 字舞流文

Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.

J. Campistol | F. Cofán | E. Rosich | M. Arias | V. Torregrosa | F. Oppenheimer

[1] Y. Seifu,et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). , 2006, Clinical nephrology.

[2] S. Mulgaonkar,et al. Patient-Reported Gastrointestinal Symptom Burden and Health-Related Quality of Life following Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium , 2006, Transplantation.

[3] J. Schold,et al. The Impact of Mycophenolate Mofetil on Long-Term Outcomes in Kidney Transplantation , 2005, Transplantation.

[4] Jeff Maca,et al. Enteric‐Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novo Renal Transplant Patients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5] R. Pelletier,et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation , 2003, Clinical transplantation.